查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1825313

乳糜瀉治療市場：2025-2030 年預測

Celiac Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 145 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

預計乳糜瀉治療市場將從 2025 年的 5.0182 億美元成長到 2030 年的 9.61137 億美元，複合年成長率為 13.88%。

乳糜瀉治療市場是消化器官系統和自體免疫疾病治療行業中一個獨特的細分市場。乳糜瀉是一種自體免疫疾病，由消化器官系統引起的小腸損傷引起，損害了脂肪、鈣、鐵和葉酸等必需營養素的吸收。這種遺傳性疾病與家族病史密切相關，例如第1型糖尿病、自體免疫甲狀腺疾病、唐氏症、類風濕性關節炎、顯微鏡下結腸炎和愛迪生氏症。

病理生理學和市場基礎

乳糜瀉是一種自體免疫疾病，其獨特的治療環境使傳統藥物療法面臨巨大挑戰。由於其遺傳基礎和複雜的免疫反應機制，麩質暴露會損害小腸粘膜，因此需要一種超越傳統藥物療法的綜合治療方法。

市場既需要解決即時症狀緩解，也需要解決患者長期營養吸收問題，而這正是患者體驗的關鍵。這種雙重治療需求為多樣化的治療方式和全面的護理解決方案創造了機會。

市場成長的關鍵驅動力

抗發炎藥物和治療性疫苗的開發是變革的驅動力，為嚴格的無麩質飲食提供了潛在的替代方案。這些創新的治療方法解決了潛在的免疫反應機制，並為超越現有飲食策略的更全面的疾病管理提供了機會。

醫療保健支出的增加和醫學研究投入的增加為市場擴張創造了有利條件。加強乳糜瀉臨床試驗和藥物研發的資金投入，將加速潛在治療方法的研發，並透過技術創新和擴大治療方案來推動市場成長。

醫療機構的醫療保健宣導活動透過提高疾病認知度和診斷率，顯著促進了市場成長。教育宣傳活動和專業培訓計畫有望加深人們對乳糜瀉症狀和診斷方法的理解，從而降低當前市場普遍存在的漏診率。

糖尿病盛行率的上升是關鍵的成長動力，因為糖尿病患者更容易患上乳糜瀉。這種相關性導致越來越多的患者需要同時治療兩種疾病的專門治療方法，從而推動了對綜合治療解決方案的需求。

飲食趨勢轉向加工食品、速食和即食包裝產品，導致一般人群麩質攝取量增加。生活方式的改變、都市化和可支配收入的增加，這些因素共同導致了飲食模式的改變，從而可能增加乳糜瀉的盛行率，從而為治療方案創造了持續的市場需求。

地理市場分佈

歐洲和北美是最大的區域市場，得益於高發病率和完善的醫療基礎設施。這些地區擁有先進的診斷能力、全面的醫療保健和強大的研發生態系統，為市場發展提供支援。

由於某些人群（尤其是撒哈拉人口）的盛行率較高，非洲擁有巨大的市場潛力，然而，有限的醫療基礎設施和診斷能力可能會影響這些地區的市場發展。

市場限制和治療挑戰

乳糜瀉特效治療方法的匱乏是市場發展的根本限制因素。缺乏能夠直接作用於自體免疫反應機制的標靶藥物療法，迫使人們必須依賴飲食管理，限制了治療方案的選擇和市場拓展潛力。

漏診和誤診率高是主要的市場障礙。由於症狀多變、診斷複雜、醫護人員認知度低，許多乳糜瀉病例仍未確診，導致大量患者未治療，因此無法滿足市場需求。

競爭格局與創新

市場上，既有像 General Mills, Inc. 和 Glenmark Pharmaceuticals Inc. 這樣的老牌藥廠，也有像 BioLineRx 這樣的新興企業進入治療開發領域。這種競爭態勢正透過夥伴關係、創新解決方案的開發以及以患者為中心的治療方法推動創新。

我們的策略性舉措致力於提升患者的舒適度和治療依從性，同時拓展傳統無麩質飲食管理以外的治療選擇。我們專注於兼顧症狀管理和生活品質的創新解決方案，為市場差異化和成長創造機會。

對戰略產業的影響

對於醫療保健專業人士而言，乳糜瀉治療市場代表著自體免疫療法、營養醫學和個人化治療方法交叉融合的機會。為了取得成功，他們必須應對診斷挑戰，同時開發超越當前飲食限制模式的創新治療方案。

本報告的主要優點

  • 深刻分析：獲得涵蓋主要和新興地區的深入市場洞察，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他細分市場。
  • 競爭格局：了解主要企業所採用的策略策略，並了解正確策略的市場滲透潛力。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力來制定策略決策，在動態環境中開闢新的業務流和收益。
  • 受眾廣泛：對於新興企業、研究機構、顧問、中小企業和大型企業來說，既有利又划算。

它有什麼用途？

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

調查範圍

  • 2022 年至 2024 年的歷史數據和 2025 年至 2030 年的預測數據
  • 成長機會、挑戰、供應鏈前景、法律規範與趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測細分市場和區域分析（包括國家）
  • 公司概況（尤其是財務狀況和關鍵發展）

目錄

第1章執行摘要

第2章市場概述

  • 市場概況
  • 市場定義
  • 調查範圍
  • 市場區隔

第3章 經營狀況

  • 市場促進因素
  • 市場限制
  • 市場機遇
  • 波特五力分析
  • 產業價值鏈分析
  • 政策法規
  • 策略建議

第4章 技術展望

5. 乳糜瀉治療市場（按類型）

  • 介紹
  • 維生素和營養補充劑
  • 類固醇
  • 免疫抑制劑
  • 治療性疫苗
  • 酵素療法
  • 無麩質飲食產品
  • 生物製藥

6. 依給藥途徑分類的乳糜瀉治療市場

  • 介紹
  • 口服
  • 注射

7. 乳糜瀉治療市場（依通路）

  • 介紹
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第8章 乳糜瀉治療市場：按地區

  • 介紹
  • 北美洲
    • 按類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家
      • 美國
      • 加拿大
      • 墨西哥
  • 南美洲
    • 按類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家
      • 巴西
      • 阿根廷
      • 其他
  • 歐洲
    • 按類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家
      • 英國
      • 德國
      • 法國
      • 西班牙
      • 其他
  • 中東和非洲
    • 按類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 其他
  • 亞太地區
    • 按類型
    • 依給藥途徑
    • 按分銷管道
    • 按國家
      • 中國
      • 日本
      • 印度
      • 韓國
      • 台灣
      • 其他

第9章競爭格局及分析

  • 主要企業和策略分析
  • 市佔率分析
  • 合併、收購、協議和合作
  • 競爭對手儀表板

第10章：公司簡介

  • Innovate Biopharmaceuticals Inc.
  • BioLineRx Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • Glutenostics LLC

第11章 附錄

  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益
  • 調查方法
  • 簡稱
簡介目錄
Product Code: KSI061610419

The Celiac Disease Treatment Market is expected to grow from USD 501.820 million in 2025 to USD 961.137 million in 2030, at a CAGR of 13.88%.

The celiac disease treatment market represents a specialized segment within the gastrointestinal and autoimmune disorder therapeutics industry. Celiac disease is characterized as a digestive autoimmune disorder that impairs the body's ability to absorb essential nutrients including fat, calcium, iron, and folate due to small intestine damage caused by gluten consumption. This gene-based inherited condition demonstrates strong correlations with family histories of type 1 diabetes, autoimmune thyroid disorders, Down syndrome, rheumatoid arthritis, microscopic colitis, and Addison's disease.

Disease Pathophysiology and Market Foundation

The autoimmune nature of celiac disease creates a unique therapeutic landscape where traditional pharmaceutical interventions face significant challenges. The condition's genetic basis and complex immune response mechanisms result in damaged small intestine lining upon gluten exposure, necessitating comprehensive treatment approaches that extend beyond conventional drug therapies.

The market's foundation rests on addressing both immediate symptom management and long-term nutritional absorption issues that define the patient experience. This dual therapeutic requirement creates opportunities for diverse treatment modalities and comprehensive care solutions.

Primary Market Growth Drivers

The development of anti-inflammatory drugs and therapeutic vaccines represents a transformative growth driver, offering potential alternatives to strict gluten-free dietary restrictions. These innovative therapeutic approaches address the underlying immune response mechanisms, providing opportunities for more comprehensive disease management beyond current dietary limitation strategies.

Rising healthcare expenditure and increased investment in medical research create favorable conditions for market expansion. Enhanced funding for clinical trials and drug development specifically targeting celiac disease accelerates the pipeline of potential therapeutic solutions, driving market growth through innovation and expanded treatment options.

Healthcare awareness initiatives by medical organizations contribute significantly to market growth through improved disease recognition and diagnosis rates. Educational campaigns and professional training programs enhance understanding of celiac disease symptoms and diagnostic approaches, potentially reducing underdiagnosis rates that currently characterize the market.

The rising prevalence of diabetes represents a critical growth catalyst, as diabetic patients demonstrate increased susceptibility to celiac disease development. This correlation creates expanded patient populations requiring specialized treatment approaches that address both conditions simultaneously, driving demand for integrated therapeutic solutions.

Dietary trend shifts toward processed foods, fast food consumption, and ready-to-eat packaged products increase gluten exposure in general populations. Lifestyle changes, urbanization, and rising disposable income contribute to dietary patterns that may increase celiac disease prevalence, creating sustained market demand for treatment solutions.

Geographic Market Distribution

Europe and North America represent the largest regional markets, supported by high disease prevalence rates and well-established healthcare infrastructure. These regions benefit from advanced diagnostic capabilities, comprehensive healthcare coverage, and robust research and development ecosystems that support market growth.

Africa presents significant market potential, particularly given the high prevalence rates observed in certain populations, such as the Saharawi people. However, healthcare infrastructure limitations and diagnostic capacity constraints may impact market development in these regions.

Market Constraints and Treatment Challenges

The limited availability of specific pharmaceutical treatments for celiac disease represents a fundamental market constraint. The absence of targeted drug therapies that directly address the autoimmune response mechanisms forces reliance on dietary management approaches, limiting therapeutic options and market expansion potential.

Significant underdiagnosis and misdiagnosis rates create substantial market barriers. Many celiac disease cases remain unidentified due to symptom variability, diagnostic complexity, and limited healthcare provider awareness, resulting in untreated patient populations that do not contribute to market demand.

Competitive Landscape and Innovation

The market features established pharmaceutical companies including General Mills, Inc. and Glenmark Pharmaceuticals Inc., alongside emerging players like BioLineRx entering the therapeutic development space. This competitive dynamic drives innovation through partnerships, novel solution development, and patient-focused treatment approaches.

Strategic initiatives focus on enhancing patient comfort and treatment adherence while expanding therapeutic options beyond traditional gluten-free dietary management. The emphasis on innovative solutions that address both symptom management and quality of life considerations creates opportunities for market differentiation and growth.

Strategic Industry Implications

For healthcare industry professionals, the celiac disease treatment market represents opportunities at the intersection of autoimmune therapeutics, nutritional medicine, and personalized treatment approaches. Success requires addressing diagnostic challenges while developing innovative therapeutic solutions that extend beyond current dietary restriction paradigms.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Celiac Disease Treatment Market Segmentation:

By Type

  • Vitamins and Dietary Supplements
  • Steroids
  • Immunosuppressive Drugs
  • Therapeutic Vaccines
  • Enzyme Therapy
  • Gluten-Free Diet Products
  • Biologics

By Route of Administration

  • Oral
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Taiwan
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. CELIAC DISEASE TREATMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Vitamins and Dietary Supplements
  • 5.3. Steroids
  • 5.4. Immunosuppressive Drugs
  • 5.5. Therapeutic Vaccines
  • 5.6. Enzyme Therapy
  • 5.7. Gluten-Free Diet Products
  • 5.8. Biologics

6. CELIAC DISEASE TREATMENT MARKET BY ROUTE OF ADMINISTRATION

  • 6.1. Introduction
  • 6.2. Oral
  • 6.3. Injectable

7. CELIAC DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies
  • 7.4. Online Pharmacies

8. CELIAC DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. By Type
    • 8.2.2. By Route of Administration
    • 8.2.3. By Distribution Channel
    • 8.2.4. By Country
      • 8.2.4.1. USA
      • 8.2.4.2. Canada
      • 8.2.4.3. Mexico
  • 8.3. South America
    • 8.3.1. By Type
    • 8.3.2. By Route of Administration
    • 8.3.3. By Distribution Channel
    • 8.3.4. By Country
      • 8.3.4.1. Brazil
      • 8.3.4.2. Argentina
      • 8.3.4.3. Others
  • 8.4. Europe
    • 8.4.1. By Type
    • 8.4.2. By Route of Administration
    • 8.4.3. By Distribution Channel
    • 8.4.4. By Country
      • 8.4.4.1. United Kingdom
      • 8.4.4.2. Germany
      • 8.4.4.3. France
      • 8.4.4.4. Spain
      • 8.4.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. By Type
    • 8.5.2. By Route of Administration
    • 8.5.3. By Distribution Channel
    • 8.5.4. By Country
      • 8.5.4.1. Saudi Arabia
      • 8.5.4.2. UAE
      • 8.5.4.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. By Type
    • 8.6.2. By Route of Administration
    • 8.6.3. By Distribution Channel
    • 8.6.4. By Country
      • 8.6.4.1. China
      • 8.6.4.2. Japan
      • 8.6.4.3. India
      • 8.6.4.4. South Korea
      • 8.6.4.5. Taiwan
      • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Innovate Biopharmaceuticals Inc.
  • 10.2. BioLineRx Ltd.
  • 10.3. Takeda Pharmaceutical Company Ltd.
  • 10.4. Glutenostics LLC

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key benefits for the stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations